Clinical trials: Resectable Prancreas Carcinoma
Resectable Prancreas Carcinoma
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
In this multicenter study, patients with resectable pancreatic carcinoma will be treated with (a) surgery followed by 6 cycles gemcitabine or (b) 4-6 cycles FOLFIRINOX followed by surgery followed by 4-6 cycles FOLFIRINOX.
- Trial name
- NCT02172976
- Testing
- Gemcitabine, Oxaliplatin, 5-Fluorouracil
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Krankenhaus Nordwest